Press Releases and News

Other published information who is not classified as regulatory news


Orexo’s OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC

6 February 2024
  • OX640 is Orexo’s nasal epinephrine powder product for the acute treatment of severe allergic reactions including anaphylaxis, based on the company´s proprietary drug delivery platform, AmorphOX®

  • The American Academy of Allergy, Asthma & Immunology (AAAAI) is the largest professional medical organization in the United States devoted to the allergy/immunology specialty

  • The AAAAI program committee selected OX640 to be presented at its late breaking oral abstract session.

Orexo is celebrating 10 years on the US Pharma market - Interview with Robert DeLuca, President of Orexo US Inc.

29 September 2023

News Release – Uppsala, Sweden, September 29, 2023
The year of 2023 marks 10 years on the US Pharma market for Orexo. In September 2013, after conscientious preparations and an FDA approval, ZUBSOLV®, became available for patients across the US. A big achievement and the start of a journey that is making a difference to the people whose lives are affected by the US opioid epidemic. In this interview, Robert DeLuca, President of Orexo US Inc., reflects on these exciting years and how he and his team are committed to tackling the opioid crisis from broad and holistic perspective.


Synthetic opioids drive record-high surge in fatal overdoses

30 August 2021

International Overdose Awareness Day, tomorrow on 31 August, is an opportunity for people across the globe to reflect on the many lives being destroyed by opioids, and the grief of their loved ones. Synthetic opioids are driving a record-high surge in fatal overdoses. With deaths caused by opioid misuse climbing to greater than 92,000[i] last year, it’s more important than ever to consider how we can prevent more broken lives.